annual meeting program - American Society of Clinical Oncology

SATURDAY
Saturday, June 5, 2010
Brd. 33C Concordance to National Comprehensive Cancer Network (NCCN) clinical
practice guidelines (GL) for imaging work-up of patients with metastatic
breast cancer: An analysis from the commercial managed care claims
PharMetrics (PM) and SEER/Medicare (SM) databases. (Abstract #1104)
D. L. McNally, B. S. Seal, J. L. Vandergrift, C. D. Mullins, E. M. Lepisto,
J. S. McClure, M. Tangirala
Brd. 34A Serum markers to monitor response to zoledronic acid in patients with bone
metastases from breast cancer. (Abstract #1105)
L. Mercatali, T. Ibrahim, E. Sacanna, R. Ricci, E. Scarpi, F. Fabbri, P. Serra,
C. Tison, D. Amadori
Brd. 34B Correlation of serum leptin level and waist-to-hip ratio (WHR) with overall
survival of patients with metastatic breast cancer (MBC) treated with
aromatase inhibitors (AIs). (Abstract #1106)
M. Artac, H. S. Bozcuk, A. Kiyici, O. O. Eren, M. C. Boruban, M. Ozdogan
Brd. 34C Quality-of-life outcomes of patients with breast cancer in an integrative
cancer treatment setting. (Abstract #1107)
E. D. Staren, D. Gupta, D. P. Braun
Brd. 35A Individualized administration of capecitabine plus lapatinib in heavily
pretreated HER2� metastatic breast cancer patients: A single-center
experience. (Abstract #1108)
P. Papaldo, G. Metro, A. Felici, M. Russillo, D. Pellegrini, A. Fabi, G. Ferretti,
M. Introna, F. Cognetti
Brd. 35B Use of SPARC, EGFR, and VEGFR expression to predict response to nabpaclitaxel
(nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triplenegative
metastatic breast cancer (TNMBC). (Abstract #1109)
E. P. Hamilton, G. G. Kimmick, N. Desai, S. Singh, J. O. Hopkins, P. K. Marcom,
V. Chadaram, R. Welch, V. N. Trieu, K. L. Blackwell
Brd. 35C Evaluation of levels of proliferating macrophages in patients at a county
hospital and those with early recurrences. (Abstract #1110)
R. Mukhtar, A. Moore, O. Nseyo, A. Au, F. L. Baehner, D. H. Moore, M. Campbell,
L. Esserman
Brd. 35D Taiwanese patients with breast cancer with brain metastasis (BM) enrolled in
the Lapatinib Expanded Access Program (LEAP). (Abstract #1111)
C. Huang, S. Chen, M. Liu, D. Yeh, M. Hou, T. Chang, R. K. Hsieh, T. Chao,
C. J. Tai, C. Tsao
Brd. 35E Low cardiotoxicity of nonpegylated liposomal doxorubicin (NPLD) in patients
(pts) with metastatic breast cancer (MBC) previously exposed to 360 mg/m 2
of doxorubicin (D). (Abstract #1112)
E. Muñoz, J. M. Perez-Garcia, C. Saura, M. Vidal, G. Sanchez-Olle, M. Bellet,
P. Gomez, S. Di Cosimo, J. Baselga, J. Cortes
Brd. 35F Efficacy of vinorelbine plus trastuzumab (VT) in patients (pts) with HER2positive
metastatic breast cancer (MBC) previously treated with trastuzumab
(T). (Abstract #1113)
V. Freixinós,G.Sánchez-Ollé, L. De Mattos-Arruda, S. Di Cosimo, C. Saura,
P. Gomez, J. M. Perez-Garcia, J. Cortes, J. Baselga, M. Bellet
Brd. 35G A regional subgroup analysis of a multinational, double-blind, randomized,
placebo-controlled, phase IIb study evaluating sorafenib (SOR) with
paclitaxel (PAC) in patients (pts) with advanced breast cancer (BC).
(Abstract #1114)
T. P. Sahoo, V. G. Kaklamani, D. Lokanatha, V. Raina, S. Bondarde, M. Jain,
L. S. Schwartzberg, W. J. Gradishar
Brd. 35H A phase I study of panobinostat (LBH589) with capecitabine with or without
lapatinib. (Abstract #1115)
N. W. Peacock, S. F. Jones, D. A. Yardley, J. C. Bendell, J. R. Infante,
P. B. Murphy, H. A. Burris III
164